Sentiment Trading

RemeGen Co Ltd has partnered with Santen Pharmaceutical to license its ophthalmic drug RC28-E, securing a significant upfront payment and potential future earnings, while expanding its global presence in the biopharmaceutical market.

RemeGen Co., Ltd. is a pioneering biotechnology company that is making significant contributions to the development of therapeutic antibody drugs, with a strong financial footing and a commitment to innovation.

RemeGen Co Ltd, a biotech leader in China, is poised to capitalize on the growing demand for autoimmune therapies through strategic partnerships and innovative solutions.